About Ivenix
Ivenix is a company based in Amesbury (United States) founded in 2001 was acquired by Fresenius Kabi in March 2022. Ivenix has raised $159.97 million across 9 funding rounds from investors including Eight Roads Ventures, 6 Dimensions Capital and F-Prime Capital. The company has 60 employees as of December 31, 2022. Ivenix offers products and services including Ivenix Infusion System and Large Volume Pump. Ivenix operates in a competitive market with competitors including Assurex Health, 410 Medical, Hospira, Hygieia and Belmont Medical Technologies, among others.
- Headquarter Amesbury, United States
- Employees 60 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ivenix, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$159.97 M (USD)
in 9 rounds
-
Latest Funding Round
$50 M (USD), Series E
Mar 17, 2017
-
Investors
Eight Roads Ventures
& 7 more
-
Employee Count
60
as on Dec 31, 2022
-
Acquired by
Fresenius Kabi
(Mar 31, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ivenix
Ivenix offers a comprehensive portfolio of products and services, including Ivenix Infusion System and Large Volume Pump.
Delivers accurate fluid control for intravenous administration
Enables precise flow measurement in clinical environments
Funding Insights of Ivenix
Ivenix has successfully raised a total of $159.97M across 9 strategic funding rounds. The most recent funding activity was a Series E round of $50 million completed in March 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series E — $50.0M
-
First Round
First Round
(31 Jul 2009)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2017 | Amount | Series E - Ivenix | Valuation |
investors |
|
| Sep, 2015 | Amount | Series D - Ivenix | Valuation | 6 Dimensions Capital | |
| Aug, 2011 | Amount | Series C - Ivenix | Valuation |
investors |
Investors in Ivenix
Ivenix has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Eight Roads Ventures, 6 Dimensions Capital and F-Prime Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life-Sciences focused early and growth stage VC firm funding companies in China & the US
|
Founded Year | Domain | Location | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Founded Year | Domain | Location | |
|
Life science & tech focused VC firm investing in early stage companies in the US
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ivenix
Financial Statements - Ivenix
Ivenix Comparisons
Competitors of Ivenix
Ivenix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Assurex Health, 410 Medical, Hospira, Hygieia and Belmont Medical Technologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Personalized medication for neuropsychiatric conditions is guided by pharmacogenomics.
|
|
| domain | founded_year | HQ Location |
Rapid infusion systems are provided for critically ill patients.
|
|
| domain | founded_year | HQ Location |
Injectable drugs, infusion technologies, and biosimilars are manufactured and supplied.
|
|
| domain | founded_year | HQ Location |
Insulin dosage guidance for diabetes is provided via handheld devices.
|
|
| domain | founded_year | HQ Location |
Fluid management and critical care medical devices are developed.
|
Frequently Asked Questions about Ivenix
Ivenix was founded in 2001 and raised its 1st funding round 8 years after it was founded.
Ivenix is headquartered in Amesbury, United States. It is registered at Amesbury, Massachusetts, United States.
Stuart Randle is the current CEO of Ivenix.
Ivenix is a funded company, having raised a total of $159.97M across 9 funding rounds to date. The company's 1st funding round was a Series C of $25M, raised on Jul 31, 2009.
As of Dec 31, 2022, the latest employee count at Ivenix is 60.
Ivenix was founded in 2001 in Amesbury, United States, within the healthcare technology sector. Infusion management systems are provided, integrating information systems into infusion devices. Wireless, web-based architecture is used to connect pumps attached to patients. Remote dashboards are accessed by nurses, pharmacists, and clinical engineers for decision support. Pump data across organizations is analyzed for quality and efficiency improvements. FDA review remains pending.
Ivenix's top competitors include 410 Medical, Belmont Medical Technologies and Hospira.
Ivenix offers Ivenix Infusion System and Large Volume Pump.
Ivenix has 8 investors. Key investors include Eight Roads Ventures, 6 Dimensions Capital, F-Prime Capital, Cardinal Partners, and Easterly Capital.